Sanofi and Regeneron’s Dupixent (dupilumab) Receive CHMP’s Positive Opinion for Moderate-To-Severe Atopic Dermatitis in Adolescents

Sanofi and Regeneron’s Dupixent (dupilumab) Receive CHMP’s Positive Opinion for Moderate-To-Severe Atopic Dermatitis in Adolescents

Shots:

  • The CHMP recommendation for approval in EU is based on LIBERTY AD program including P-III study & an open-label ext. study assessing Dupixent in adolescents aged 12-17 yrs. with uncontrolled AD
  • Post-approval, Dupixent will be the first biologic to be approved in the EU for the treatment of AD with its expected EMA’s decision in coming months
  • Dupixent is a mAb targeting IL-4 & IL-13 and has received approval in the multiple countries including the US, EU and Japan for mod. to sev. AD and asthma

Click here to read full press release/ article | Ref: Sanofi | Image: Arabian Business